The authors surveyed the pattern of care (POC) of lung cancer (LC) using data on 4565 patients from the cancer registry of their university-affiliated hospital institution for the period of 1991 to 2002. New clinical evidence was retrieved from the citations used in the level 1 recommendations in guidelines and textbooks. Using this evidence, indexes (1-6) were chosen, including stage I to II non-small-cell LC (NSCLC): no adjuvant radiotherapy (ART; I); stage III NSCLC: equivocal ART (II), neoadjuvant chemotherapy (C/T; III), and chemoradiotherapy (CRT; IV); stage 4 NSCLC: C/T (V) and limited-stage small-cell LC: CRT (VI). Odds ratios of these index events in the postevidence period versus preevidence period were calculated to show trends in the POC. Trends in the POC were consistent with new clinical evidence with statistical significance. The age and gender adjustment odds ratio was 2.22 to 7.06 for beneficial indexes (3-6) and 0.12 to 0.4 for detrimental indexes (1-2).
World Health Organization. The World Health Report 2004. New York, NY: World Health Organization; 2005. Available at: http://www.who.int/whr/2004/annex/topic/annex2.xls. Accessed November 15, 2005.
2.
Cartman ML, Hatfield AC, Muers MF, et al.Lung cancer: district active treatment rates affect survival. J Epidemiol Community Health. 2002;56: 424-429.
3.
Mahmud SM, Reilly M, Comber H.Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer. 2003;41: 57-64.
4.
Ford LG, Hunter CP, Diehr P, Frelick RW, Yates J.Effects of patient management guidelines on physician practice patterns: the Community Hospital Oncology Program experience. J Clin Oncol. 1987;5;504-511.
5.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology—non-small cell lung cancer v.1.2004. Available at: Http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed September 1, 2004.
6.
Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, eds. SEER Summary Staging Manual—2000: Codes and Coding Instructions [NIH Pub No. 01-4969]. Bethesda, Md: National Cancer Institute; 2001.
7.
Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed.New York, NY: Spriger-Verlag; 2002.
8.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology—small cell lung cancer v.1.2004. Available at: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf. Accessed September 1, 2004.
9.
National Cancer Institute. Non-small cell Lung Cancer (PDQ®): Treatment. Bethesda, Md: National Cancer Institute; 2004. Available at: http://www.nci.nih.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional. Accessed September 1, 2004.
10.
National Cancer Institute. Small Cell Lung Cancer (PDQ®): Treatment. Bethesda, Md: National Cancer Institute; 2004. Available at: http://www.nci.nihgov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional. Accessed September 1, 2004.
PORT Meta-analysis Trialists Group. Postoperative radio-therapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352: 257-263.
13.
Non-small cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer (Cochrane Review). In: Cochrane Library, Issue 2. Oxford, UK: Update Software; 2002.
14.
Goss G, Paszat L, Newman TE, Evans WK, Browman G.Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Cancer Prev Control. 1998;2: 32-39.
15.
Dillman RO, Seagren SL, Propert KJ, et al.A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323: 940-945.
16.
Le Chevalier T, Arriagada R, Quoix E, et al.Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83: 417-423.
17.
Furuse K, Fukuoka M, Kawahara M.Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17: 2692-2699.
18.
Curran WJ, Scott CB, Langer CJ, et al.Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [abstract]. Proc Am Soc Clin Oncol. 2003;22: 621-621. Abstract 2499.
19.
Saunders M, Dische S, Barrett A, et al.Continuous hyper-fractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet. 1997;350: 161-165.
20.
Souquet PJ, Chauvin F, Boissel JP, et al.Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993;342: 19-21.
21.
Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F.Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest. 1994;106: 861-865.
22.
Weick JK, Crowley J, Natale RB, et al.A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1991;9: 1157-1162.
23.
Schiller JH, Harrington D, Belani CP, et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346: 92-98.
24.
Warde P, Payne D.Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10: 890-895.
25.
Pignon JP, Arriagada R, Ihde DC, et al.A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327: 1618-1624.
26.
Turrisi AT III, Kim K, Blum R, et al.Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etopo-side. N Engl J Med. 1999;340: 265-271.
27.
Klasa RJ, Murray N, Coldman AJ.Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991;9: 499-508.
28.
Murray N, Livingston RB, Shepherd FA, et al.Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999;17: 2300-2308.
29.
Noda K, Nishiwaki Y, Kawahara M, et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346: 85-91.
30.
Auperin A, Arriagada R, Pignon JP, et al.Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341: 476-484.
31.
Spira A, Ettinger DS.Multidisciplinary management of lung cancer. N Engl J Med. 2004;350: 379-392.
32.
Alexanian A, Torri V.Survey on the treatment of non-small-cell lung cancer in Italy. Ann Oncol. 2000;11: 807-813.
33.
Hall SE, Bulsara CE, Bulsara MK, et al.Treatment patterns for cancer in Western Australia: does being indigenous make a difference?Med J Aust. 2004;181: 191-194.
34.
Movsas B, Moughan J, Komaki R, et al.Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol. 2003;21: 4553-4559.
35.
Earle CC, Venditti LN, Neumann PJ, et al.Who gets chemotherapy for metastatic lung cancer?Chest. 2000;117: 1239-1246.
36.
Potosky AL, Saxman S, Wallace RB, Lynch CF.Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol. 2004;22: 3261-3268.
37.
Hoverman JR, Robertson SM.Lung cancer: a cost and outcome study based on physician practice patterns. Dis Manag. 2004;7: 112-123.
38.
Smith TJ, Penberthy L, Desch CE, et al.Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995;13: 235-252.
39.
PubMed. Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=PubMed. Accessed March 11, 2006.
40.
Kedikoglou S, Syrigos K, Skalkidis Y, Ploiarchopoulou F, Dessypris N, Petridou E.Implementing clinical protocols in oncology: quality gaps and the learning curve phenomenon. Eur J Public Health. 2005;15: 368-371.
41.
Langer CJ, Moughan J, Movsas B, et al.Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?Lung Cancer. 2005;48: 93-102.
42.
Lee J, Marchbank A, Goldstraw P.Implementation of the British Thoracic Society recommendations for organising the care of patients with lung cancer: the surgeon’s perspective. Ann R Coll Surg Engl. 2002;84: 304-308.
43.
Mainz J, Krog BR, Bjornshave B, Bartels P.Nationwide continuous quality improvement using clinical indicators: the Danish National Indicator Project. Int J Qual Health Care. 2004;16(suppl 1): i45-i50.
44.
Teshima T.Patterns of care study in Japan. Jpn J Clin Oncol. 2005;35: 497-506.
45.
Edwards BK, Brown ML, Wingo PA, et al.Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97: 1407-1427.
46.
Spiro SG, Silvestri GA.One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172: 523-529.
47.
Berghmans T, Paesmans M, Meert AP.Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49: 13-23.
48.
Mainz J, Bartels PD.Nationwide quality improvement—how are we doing and what can we do?Int J Qual Health Care. 2006;18: 79-80.
49.
Tang ST, Tsai CM, Chung KP, Lai MS.Establishment of quality indicators for non-small cell lung cancer care [in Chinese]. Thoracic Medicine. 2004;19: 463-475.
